New and investigational triazole agents for the treatment of invasive fungal infections

Journal of Chemotherapy

Volumn 20, Issue 6, 2008, Pages 661-671

  De Sarro, Angelina ^a   La Camera, E ^b   Fera, M T ^b  

^a Dipartimento Clinico Sperimentale di Medicina e Farmacologia   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Albaconazole; Invasive fungal infections; Isavuconazole; Posaconazole; Ravuconazole; Voriconazole

Indexed keywords

4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; ALBACONAZOLE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; OMEPRAZOLE; PHENOBARBITAL; PIMOZIDE; PLACEBO; POSACONAZOLE; RANITIDINE; RAVUCONAZOLE; RIFAMPICIN; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; TERFENADINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HALLUCINATION; HIGH RISK POPULATION; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER TOXICITY; METABOLIC DISORDER; MICROBIOLOGY; MYCOSIS; NAUSEA; PHOTOSENSITIVITY DISORDER; PROTEIN SYNTHESIS INHIBITION; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VOMITING;

EID: 59449096274     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.6.661     Document Type: Review

References (115)

1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33(5): 641-647.
2. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care (Engl) 2001; 10(1): 56-62.
3. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006; 15(6): 579-602.
4. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infection 2004; 10: 1-10.
5. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008; 61 Suppl 1: i19-30.
6. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents. 2007; 30(2): 108-17.
7. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004; (3): CDO04291.
8. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Investig Drugs 2000; 9(8): 1797-1813.
9. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Amé S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005; 56 Suppl 1: i39-i48.
10. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12(1): 40-79.
11. Lamb D, Kelly D, Kelly S. Molecular aspects of azole antifungal action and resistance. Drug Resist Updat 1999; 2(6): 390-402.
12. Hof H. A new, broad-spectrum azole antifungal: posaconazole-mechanisms of action and resistance, spectrum of activity. Mycoses 2006; 49 Suppl 1: 2-6.
13. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42(10): 4419-4431.
14. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M. Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36 Suppl. 1: 119-128.
15. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12(4): 501-517.
16. VFEND (voriconazole) tablets and injection [package insert). New York: Pfizer, Inc, 2002.
17. Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25(5): 1321-1381.
18. Wildfeuer A, Seidl HP, Paule I, Haberreiter A. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998; 41(7-8): 309-319.
19. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dennatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39(1): 385-388.
20. Donnelly JP, De Pauw BE. Voriconazole - a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infection 2004; 10(1): 107-117.
21. Kauffman CA, Zarins LT. In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 1998; 31(1): 297-300.
22. Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 1999; 33(1): 7-11.
23. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother 2002; 46(6): 1723-1727.
24. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48(3): 201-205.
25. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44(5): 1782-1787.
26. Kaya AD, Kiraz N. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole. Mycoses 2007; 50(6): 447-450.
27. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999; 37(12): 3946-3951.
28. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob Agents Chernother 2000; 44(6): 1734-1736.
29. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39(3): 954-958.
30. Capilla J, Ortoneda M, Pastor FJ, Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 2001; 45 (9): 2635-2637.
31. Guinea J, Pelaez T, Recio S, Torres-Narbona, M, Bouza E. In vitro antifungal activity of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52(4): 1396-1400.
32. Krishnan S, Manavathu EK, Chandrasekar PH. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus. J Antimicrob Chemother 2005; 55(6): 914-920.
33. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000; 44(7): 1917-1920.
34. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42(4): 395-402.
35. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose, escalation regimens. Antimicrobials Agents Chemotherapy 2002; 46(8): 2546-2553.
36. Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multipledose oral voriconazole. Br J Clin Pharmacol 2003; 56 Suppl 1: 17-23.
37. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 Suppl 1: 10-16.
38. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31(5): 540-712.
39. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Nakashima M. Pharmacokinetics of voriconazole and cytocrome P450 and 2C19 genetic status. Clin Pharmacol Ther 2004; 75(6): 586-588.
40. Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (BUMC) 2003; 16(2): 241-248.
41. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34(5): 563-571.
42. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-415.
43. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39(2): 192-198.
44. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33(9): 1447-1454.
45. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366(9495): 1435-1442.
46. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients With neutropenia and persistent fever. N Engl J Med 2002; 346(4): 225-234. Erratum in: N Engl J Med 2007; 356(7): 760.
47. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voricoriazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36(9): 1122-1131.
48. Imhof A, Schaer DJ, Schanz U, Schwarz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006;136(45-46):739-42.
49. Voriconazole: serious adverse effects and interactions. Prescribe Int. 2007; 16(87): 18.
50. Denning DW, Griffiths CE. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exper Dermatol 2001; 26(8): 648-653.
51. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44(5): 55-56.
52. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;56 Suppl 1:24-9.
53. Yakiwchuk EM, Foisy MM, Hughes CA. Complexity of interactions between voriconazole and antiretroviral agents. Ann Pharmacother 2008;42(5):698-703.
54. Tintillier M, Kirk L, Goffin E, Cuvelier C, Pochet JM. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant 2005;20(3):664-5.
55. Romero AJ, Le Pogamp P, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2004;75(6):587-8.
56. Bennett F, Saksena AK, Lovey RG, Liu YT, Patel NM, Pinto P, et al. Hydroxylated analogues of the orally active broad spectrum antifungal, Sch51048(1), and the discovery of posaconazole (Sch 56592; 2 or [S,S]-5). Bioorg Med Chem Lett 2006; 16(1):186-190.
57. Noxafil [package insert]. Kenilworth, Schering Corporation, 2006).
58. Schering-Plough news release. Schering-Plough announces FDA approval of NOXAFIL (posaconazole) for treatment of oropharyngeal candidiasis (OPC). Kenilworth, NJ: Schering-Plough; October 2006. Available at: http://www.schering-plough.com/schering_plough/news/ release.jsp?releaseID=919520. Accessed January 10, 2006)
59. Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5(12):775-785.
60. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzan A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50(3): 917-921.
61. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41(8): 3623-3626.
62. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50(6):2009-2015.
63. Lortholary O, Dannaoui E, Raoux D, Hoinard D, Dairy A, Paugam A, et al. In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the european committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2007; 51(9): 3378-3380.
64. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008; 46(2): 551-559.
65. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004; 58(6):612-624.
66. Pfaller MA, Messer SA, Hollis RJ, Jones RN; SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.Antimicrob Agents Chemother 2002; 46(4):1032-1037.
67. Pfaller MA, Messer SA, Boyken L, Rice C, Tendotkar S, Hollis RJ, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol. 2005; 43(5): 2163-2167.
68. Gonzàlez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005; 43(3): 281-284.
69. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrobial Agents Chemother 2003; 47(9): 2788-2795.
70. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics, of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrobial Agents Chemother 2004; 48(3): 804-808.
71. Ezzet F., Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage reccomandations. Clin Pharmacokinet 2005; 44(2): 211-220.
72. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, et al. Effects of nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. of posaconazole in healthy volunteers Antimicrobial Agents Chemother 2006; 50(5): 1881-1883.
73. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy men. Antimicrobial Agents Chemother 2004; 48(9): 3543-3551.
74. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56(4): 745-755.
75. Lodge BA, Ashley ED, Steele MP, Perfect JR. Aspergillus fumigatus empyema, arthritis and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole. J Clin Microbiol 2004; 42(3): 1376-1378.
76. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole (SDH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86(7): 829-830.
77. Ulmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, et al. Pharmacokinetics, safety and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrobial Agents Chemother 2006; 50(2): 658-666.
78. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32(2): 267-271.
79. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two way crossover study. Eur J Pharm Sci 2004; 21(5): 645-653.
80. Sansone-Parsons A, Krishna G, Simon J, Soni P, Kantesaria B, Herron J, et al. Effects of age, gender and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrobial Agents Chemother 2007; 51(2): 495-502.
81. Walsh T, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44(1): 2-12.
82. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus host disease. N Engl J Med 2007; 356(4): 335-347.
83. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348-359.
84. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007; 44(4): 607-614.
85. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/ AIDS. Clin Infect Dis 2006; 42(8): 1179-1186.
86. Page RL 2nd, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007; 27(2): 290-298.
87. Rutar T, Cockerham KP. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am J Ophthalmol 2006; 142(1):187-188.
88. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Walter J, Letscher-Bru V. Successful treatment of Fusariun proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23(12): 1451-54.
89. Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143(2): 222-227.
90. Raad I, Graybill JR, Bustamante AB, Cornely OA, Gaona-Flores V, Afif C, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42(12): 1726-1734.
91. Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27(6):825-34.
92. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008; 52(4): 1580-1582. Epub 2008 Jan 22.
93. Seifert H, Aurbach U, Stefanik D, Comely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 51(5): 1818-21.
94. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(l): 279-285.
95. Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusio and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(1): 286-293.
96. Viljoen JJ, Mitha I, Heep M, et al. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotheraphy, Washington, DC, 2005. Washington, DC, USA: American Society for Microbiology. Abstract LB2-32.
97. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother 1998; 42(2): 313-318.
98. Yamazumi T, Pfaller MA, Messer SA, Houston A, Hollis RJ, Jones RN. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44(10): 2883-2886.
99. Moore CB, Walls CM, Denning W. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000; 44(2): 441-443.
100. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, L. Rodriguez-Tudela J. In vitro activities of ravuconazole and four other antifungal agents against fluconazole -resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother 2004; 48(8): 3107-3111.
101. Minassian B, Huczko E, Washo T, Bonner D, Fung-Tomc J. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin Microbiol Infect 2003; 9(12): 1250-1252.
102. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005; 49(12):5136-5138.
103. Grasela DM, Olsen SJ, Mummaneni V et al. Ravuconazole: multiple ascending oral dose study in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobal Agents and Chemotherapy, Toronto, Canada, 2000. Washington, DC, USA: American Society for Microbiology. Abstract A-839.
104. Marino M, Mummaneni V, Norton J, Hadjilambris O, Pierce P. Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis (Abstract J-1622). In: American Society for Microbiology 2001. Chicago, IL, 2001:393.
105. Bello A, Russo R, Grasela DM et al. Pharmacokinetics of intravenous BMS-379224 (pro-drug of ravuconazole) in healthy male subjects. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Washington, DC, USA: American Society for Microbology. Abstract A-1567.
106. Olsen SJ, Mummaneni V, Rolan P, et al. Ravuconazole single ascending oral dose study in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Washington, DC, USA: American Society for Microbiology. Abstract A-838.
107. Beale M, Queiroz-Telles F, Banhegyi D, et al. Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2001. Washington, DC, USA: American Society for Microbiology. J-1621.
108. Gupta AK, Leonardi C, Stoltz RR, Pierce PF, Conetta B; Ravuconazole onychomycosis group. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19(4): 437-443.
109. Ramos G, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999; 44(2):283-286.
110. Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK Jr., et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004; 48(2): 384-387.
111. Garau M, Pereiro M Jr., del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR9825), and other antifungal compounds. Antimicrob Agents Chemother 2003; 47(7): 2342-2344.
112. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against [i Fusarium spp. Diagn Microbiol Infect Dis. 2004; 48(1):69-71.
113. Chen A, Sobel JD. Emerging azole antifungals. Expert Opin Emerg Drugs 2005; 10(1): 21-33.
114. Izquierdo I, Lurigados C, Perez I, et al. First administration into man of UR-9825: a new triazole class of antifungal agent. In: Abstracts of the Sixth Congress of the European Confederation of Medical Mycology Societies (ECMM), Barcelona, Spain, 2000. P2-004.
115. Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fluconazole 150 mg single dose in acute vulvovaginal candidiasis. In: Abstracts of the Forty-fifth Interscience Conference on Antimicriobial Agents and Chemotherapy, Washington, DC, 2005. Washington, DC, USA: American Society for Microbiology. Abstract M-722.